Proactive Investors - Run By Investors For Investors

Spate of contract wins helps to drive top-line growth at IXICO

IXICO’s revenues rose 32% to £5.4mln in the 12 months ended September 30, boosted by the signing of several lucrative contracts
brain mri scan
The company's technology manages and helps interpret images from MRI and positron emission tomography as well as collating and making sense of biosensor data

A growing adoption of its medical imaging technology helped IXICO Plc’s (LON:IXI) top-line surge last year.

In a pre-close trading update, the AIM company revealed that revenues rose 32% to £5.4mln in the 12 months ended September 30 (2017: £4.1mln). Total income rose 25% to £6.0mln (2017: £4.8mln).

READ: IXICO trading ahead of expectations

During the year, IXICO announced several contracts worth over £15mln, including a recent £9.1mln deal to provide insight from magnetic resonance imaging (MRI) data to assist in phase III clinical trial for a drug to treat Huntington's disease.

“These new contracts and existing projects provide a foundation for future revenue growth,” read Monday’s statement.

Net cash at the end of September totalled £7.9mln (2017: £2.4mln), reflecting an oversubscribed £5.5mln placing back in May as well as an R&D tax credit receipt of £0.4mln.

The full set of results are scheduled to published on December 4.

View full IXI profile View Profile

IXICO PLC Timeline

Newswire
December 11 2018

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use